Safety of Switching From Rituximab to Ocrelizumab in MS Patients
Status:
Completed
Trial end date:
2019-03-06
Target enrollment:
Participant gender:
Summary
This is a prospective between and within group observational study to determine differences
in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS)
patients who have been administered at least two infusions of rituximab, six months apart and
are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on
rituximab as a comparison cohort from the clinic population treated as part of clinical care.